Drug-induced lupus erythematosus epidemiology and demographics

Jump to navigation Jump to search

Drug-induced lupus erythematosus Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Drug-induced lupus erythematosus from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Drug-induced lupus erythematosus epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Drug-induced lupus erythematosus epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Drug-induced lupus erythematosus epidemiology and demographics

CDC on Drug-induced lupus erythematosus epidemiology and demographics

Drug-induced lupus erythematosus epidemiology and demographics in the news

Blogs on Drug-induced lupus erythematosus epidemiology and demographics

Directions to Hospitals Treating Drug-induced lupus erythematosus

Risk calculators and risk factors for Drug-induced lupus erythematosus epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Cafer Zorkun, M.D., Ph.D. [2]

Overview

Prevalence

  • In the U.S.: As many as 10% of the approximately 500,000 cases of SLE may be DIL.
  • It is estimated that 6 to 12% of all SLE cases are of drug-induced lupus type. The incidence has been reported to be of 15,000 to 30,000 per year in the U.S..[1]

Case-Fatality Rate

  • There is no information about case-fatality rate on drug-induced lupus, but it can be potentially fatal. 16466117 [2]

Age

Patients with DILE tend to be older (50–70 years old) than those with SLE (average age 29 years at diagnosis). Elderly persons generally are more susceptible to DILE.

Gender

In DIL, no significant statistical difference is apparent in the prevalence for males versus females. In contrast, SLE affects women with considerably higher frequency than men (female-to-male ratio of 9:1).

Ethnicity

More whites than blacks develop DIL; more blacks than whites present with SLE.

References

  1. "StatPearls". 2021. PMID 28722919.
  2. Finks SW, Finks AL, Self TH (2006). "Hydralazine-induced lupus: maintaining vigilance with increased use in patients with heart failure". South Med J. 99 (1): 18–22. doi:10.1097/01.smj.0000197121.12352.19. PMID 16466117.


Template:WikiDoc Sources